“New” Plan B Emails Say FDA’s “Novel” Concerns Were Not Novel – Waxman
This article was originally published in The Tan Sheet
Executive Summary
Internal emails suggest FDA began addressing legal issues pertaining to "dual marketing" of Plan B in early 2004; these documents could strengthen the Center for Reproductive Rights' suit against the agency over the delay in considering OTC status for the drug